Diego Villa, MD, MPH, discusses the rationale for a retrospective analysis evaluating bendamustine plus rituximab as induction therapy in patients with mantle cell lymphoma.
Diego Villa, MD, MPH
Advertisement
Articles by Diego Villa, MD, MPH
Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, Department of Medicine, The University of British Columbia, discusses the use of bendamustine and rituximab (Rituxan) as induction therapy in mantle cell lymphoma (MCL).
Diego Villa, MD, MPH, discusses the findings of a retrospective analysis looking at bendamustine plus rituximab in mantle cell lymphoma.
Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, Department of Medicine, The University of British Columbia, discusses the efficacy of induction therapy with bendamustine plus rituximab (Rituxan) in mantle cell lymphoma (MCL).
Diego Villa, MD, MPH, discusses a retrospective analysis of bendamustine and rituximab as induction therapy in patients with transplant-eligible and -ineligible mantle cell lymphoma.
Advertisement
Latest Updated Articles
Dr. Villa on Induction Therapy With Bendamustine/Rituximab in MCLPublished: January 15th 2020 | Updated:
Dr. Villa on the Efficacy of Induction Therapy With BR in MCLPublished: February 5th 2020 | Updated:
Dr. Villa on Retrospective Data of Bendamustine/Rituximab in MCLPublished: March 10th 2020 | Updated:
Dr. Villa on the Use of BR as Induction Therapy in MCLPublished: April 9th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5